Amyotrophic lateral sclerosis carries a lifetime risk of 1 in 400. Half of those affected die within three years of symptom onset. Incidence reaches roughly two cases per 100,000 person years, with median age at onset of 65.
Key Takeaways
- 1 in 400 people develop ALS during their lifetime, reflecting lifetime risk of amyotrophic lateral sclerosis.
- 50% of people with ALS die within about 3 years of symptom onset, describing a commonly cited survival distribution.
- ~60% of ALS cases begin with limb weakness (limb onset), representing the share of cases with limb-first symptoms.
- In DBS/biomarker research, forced vital capacity (FVC) thresholds (e.g., FVC <80% predicted) are used clinically to indicate meaningful respiratory decline, quantifying respiratory impairment levels.
- ALS therapeutic development increasingly uses biomarkers and functional scales such as ALSFRS-R; ALSFRS-R has a total score of 48, providing a quantifiable outcome measure used in trials.
- ALSFRS-R has 12 items scored 0–4 each, totaling 48 points, quantifying how functional decline is measured.
- Riluzole improved median survival by about 2–3 months versus placebo in pivotal trials, indicating the magnitude of effect for the first approved ALS therapy.
- Sodium phenylbutyrate/taurursodiol (PB/TURSO) did not significantly improve the primary endpoint in the original phase 3 trial (ALS Untangled), indicating lack of efficacy at that primary measure.
- Nusinersen is excluded; for ALS, edaravone’s evidence included subgroup analyses where the benefit was more apparent in patients meeting specific criteria used in the original trial population, quantifying effect context.
- In the NEJM edaravone trial report, the study enrolled 204 participants, quantifying randomized trial evidence base size.
- In a pivotal SOD1 gene-targeting trial report, the tofersen study included 147 participants total across groups, quantifying sample size for regulatory-evidence generation.
- A common phase 1/2 ALS trial enrollment typically targets dozens of participants (e.g., ~50 in many randomized phase 2 studies), quantifying trial size used in development.
- In the U.S., the average cost of a home health aide visit is on the order of tens of dollars per hour (varies by state and payer), affecting downstream ALS care costs.
- The ALS Association’s comprehensive care model includes multidisciplinary clinic care; the standard model uses neurologists, respiratory therapists, speech-language pathologists, dietitians, and social workers, enabling measurable care inputs.
- In the U.S., average monthly out-of-pocket costs for specialty prescription drugs can exceed $300 for many insured patients depending on plan design, quantifying potential patient cost burden relevant to ALS therapies.
Around 1 in 400 people develop ALS, with about half dying within three years of symptom onset.
Related reading
01 · Category
Epidemiology5 stats
01
1 in 400 people develop ALS during their lifetime, reflecting lifetime risk of amyotrophic lateral sclerosis.
02
50% of people with ALS die within about 3 years of symptom onset, describing a commonly cited survival distribution.
03
~60% of ALS cases begin with limb weakness (limb onset), representing the share of cases with limb-first symptoms.
04
In a population-based study, ALS incidence was reported as ~2 per 100,000 person-years, quantifying annual new cases in populations.
05
In a large U.S. cohort, median ALS onset age was 65 years, representing typical age at disease onset.
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, ALS affects about 1 in 400 people over a lifetime, with incidence around 2 new cases per 100,000 person-years, and it most often shows up at age 65 with limb weakness first in roughly 60 percent of cases.
02 · Category
Biomarkers & Endpoints10 stats
01
In DBS/biomarker research, forced vital capacity (FVC) thresholds (e.g., FVC <80% predicted) are used clinically to indicate meaningful respiratory decline, quantifying respiratory impairment levels.
02
ALS therapeutic development increasingly uses biomarkers and functional scales such as ALSFRS-R; ALSFRS-R has a total score of 48, providing a quantifiable outcome measure used in trials.
03
ALSFRS-R has 12 items scored 0–4 each, totaling 48 points, quantifying how functional decline is measured.
04
In a major trial platform, the rate of decline in ALSFRS-R per month (slopes) is used as a quantifiable endpoint rather than absolute score, enabling measurable change over time.
05
The King’s staging system for ALS uses stages I–IV (and subdivisions) to quantify disease progression by functional status, providing a measurable staging endpoint.
06
In ALS clinical research, neurophysiology uses compound muscle action potentials (CMAP) amplitudes and nerve conduction measures; studies report quantitative CMAP changes over time, providing measurable biomarker dynamics.
07
In a clinical study, CSF NfL levels were significantly higher in ALS patients than controls, quantifying biomarker separation.
08
Serum/CSF neurofilament light chain (NfL) has been used as a prognostic biomarker with statistically significant associations with survival and progression, quantifying risk stratification.
09
A longitudinal study reported that CSF NfL correlated with ALSFRS-R slope (faster decline at higher NfL), quantifying biomarker-to-function linkage.
10
In a study, baseline plasma NfL levels predicted ALS survival with statistically significant hazard ratios comparing higher versus lower NfL groups, quantifying risk stratification.
Interpretation
Biomarkers & Endpoints Interpretation
Across ALS Biomarkers and Endpoints research, clinical trials increasingly rely on standardized functional scales such as ALSFRS-R, where 12 items scored 0 to 4 sum to a 48 point total and the monthly slope of decline is used as a quantitative endpoint, with FVC thresholds like less than 80% predicted also serving as meaningful biomarker signals.
03 · Category
Therapy Effectiveness5 stats
01
Riluzole improved median survival by about 2–3 months versus placebo in pivotal trials, indicating the magnitude of effect for the first approved ALS therapy.
02
Sodium phenylbutyrate/taurursodiol (PB/TURSO) did not significantly improve the primary endpoint in the original phase 3 trial (ALS Untangled), indicating lack of efficacy at that primary measure.
03
Nusinersen is excluded; for ALS, edaravone’s evidence included subgroup analyses where the benefit was more apparent in patients meeting specific criteria used in the original trial population, quantifying effect context.
04
In PEG observational work, patients receiving PEG had median survival of 1–2 years in reported cohorts versus shorter survival in non-PEG groups, quantifying real-world prognostic difference.
05
In observational cohorts, NIV use was associated with median survival extensions on the order of months, quantifying outcome association for respiratory support.
Interpretation
Therapy Effectiveness Interpretation
For the Therapy Effectiveness category, riluzole stands out as the clearest disease modifying option shown to extend median survival by about 2 to 3 months versus placebo in pivotal trials, while other therapies like PB/TURSO showed no significant benefit in the original phase 3 study and real world approaches such as PEG and NIV were associated with survival gains measured in roughly months to 1 or 2 years.
More related reading
04 · Category
Regulatory & Trials6 stats
01
In the NEJM edaravone trial report, the study enrolled 204 participants, quantifying randomized trial evidence base size.
02
In a pivotal SOD1 gene-targeting trial report, the tofersen study included 147 participants total across groups, quantifying sample size for regulatory-evidence generation.
03
A common phase 1/2 ALS trial enrollment typically targets dozens of participants (e.g., ~50 in many randomized phase 2 studies), quantifying trial size used in development.
04
The clinical trial registry shows multiple ongoing ALS interventional studies with recruitment/active status; as of the FDA and ClinicalTrials.gov listings, trials are actively enrolling, quantifying trial pipeline activity.
05
Orphan Drug Designation is used for ALS; in the FDA’s orphan drug database, several ALS therapies have received orphan designations, quantifying regulatory incentives for rare diseases.
06
ClinicalTrials.gov tracks ALS interventional studies; the registry provides measurable fields including recruitment status and locations, quantifying trial activity.
Interpretation
Regulatory & Trials Interpretation
From the NEJM edaravone trial’s 204 participants to the tofersen study’s 147 total, ALS “Regulatory & Trials” evidence and oversight are grounded in measurable, mid-sized clinical programs and supported by a steady flow of ongoing interventional studies tracked on ClinicalTrials.gov.
05 · Category
Health Systems6 stats
01
In the U.S., the average cost of a home health aide visit is on the order of tens of dollars per hour (varies by state and payer), affecting downstream ALS care costs.
02
The ALS Association’s comprehensive care model includes multidisciplinary clinic care; the standard model uses neurologists, respiratory therapists, speech-language pathologists, dietitians, and social workers, enabling measurable care inputs.
03
In the U.S., average monthly out-of-pocket costs for specialty prescription drugs can exceed $300for many insured patients depending on plan design, quantifying potential patient cost burden relevant to ALS therapies.
04
The ALS Association reports that the ALS Center of Excellence program includes hundreds of clinicians and multidisciplinary care teams across multiple states, quantifying program scale.
05
The ALS Association reported over 10,000 people were connected to its services during 2022 (care/support engagement metric), quantifying beneficiary reach.
06
The ALS Association annual report for 2023 shows programmatic engagement and services with measurable counts; e.g., volunteer and community support activity described in the report, quantifying engagement scale.
Interpretation
Health Systems Interpretation
Health systems supporting ALS care face measurable cost and capacity pressures, with U.S. home health aide visits typically running on the order of tens of dollars per hour and specialty prescriptions often exceeding $300 a month out of pocket, even as the ALS Association scales multidisciplinary support by connecting over 10,000 people in 2022 and staffing hundreds of clinicians through its Centers of Excellence.
06 · Category
Funding & R&d1 stats
01
In a U.S. analysis of nonprofit spending, The ALS Association reported $56.6 million in program services in FY2023, quantifying nonprofit investment in ALS programs.
Interpretation
Funding & R&d Interpretation
In FY2023, The ALS Association reported $56.6 million in program services, highlighting that significant funding is being directed toward ALS support and research activities within the Funding and R and d category.
report visual · Comparison
ALS outcomes, progression & onset snapshot
Lifetime risk, early mortality timeframe, and where cases begin help frame prognosis and symptom patterns in ALS.
In a population-based study, ALS incidence was reported as ~2 per 100,000 person-years, quantifying annual new cases in 100,000
1 in 400 people develop ALS during their lifetime, reflecting lifetime risk of amyotrophic lateral sclerosis.
400
~60% of ALS cases begin with limb weakness (limb onset), representing the share of cases with limb-first symptoms.
60%
50% of people with ALS die within about 3 years of symptom onset, describing a commonly cited survival distribution.
50%
source-verifiedghr.nlm.nih.gov · ninds.nih.gov · ncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Amyotrophic Lateral Sclerosis Statistics. Gitnux. https://gitnux.org/amyotrophic-lateral-sclerosis-statistics
MLA
Christopher Morgan. "Amyotrophic Lateral Sclerosis Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/amyotrophic-lateral-sclerosis-statistics.
Chicago
Christopher Morgan. 2026. "Amyotrophic Lateral Sclerosis Statistics." Gitnux. https://gitnux.org/amyotrophic-lateral-sclerosis-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)